Elan Says It Has Cured Tysabri Contract Breach
Elan announced Monday that the “unintended” breach had been cured by amending a contract with Johnson & Johnson to exclude a section related to Tysabri, a multiple sclerosis drug jointly marketed by Elan and Biogen.
A spokeswoman for Biogen declined to comment on her company’s position on the purported contract cure.
The July 2...
To view the full article, register now.